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Abstract 
Articular conditions are common in horses and can result in loss of function, chronic pain 
and/or inability to work. Common conditions include osteoarthritis, osteochondrosis and 
synovial sepsis, which can be life-threatening, but despite the high clinical prevalence of 
these conditions, rapid and specific diagnosis, monitoring and prognostication remains a 
challenge for practicing veterinarians. Synovial fluid from a range of arthropathies was 
enriched for low abundance proteins using combinatorial peptide ligand ProteoMiner™ 
beads and analysed via liquid chromatography-tandem mass spectrometry. Changes in 
protein abundances were analysed using label-free quantification. Principle component 
analysis of differentially expressed proteins identified groupings associated with joint 
pathology. Findings were validated using ELISA. Lactotransferrin (LTF) abundance was 
increased in sepsis compared to all other groups and insulin-like growth factor-binding 
protein 6 (IGFBP6) abundance decreased in sepsis compared to other disease groups. 
Pathway analysis identified upregulation of the complement system in synovial joint sepsis  
and the downregulation of eukaryotic translation initiation factors and mTOR signall ing 
pathways in both OA and OC compared to the healthy group. Overall,  we have identified a 
catalogue of proteins which we propose to be involved in osteoarthritis, osteochondrosis 
and synovial sepsis pathogenesis.  
Significance 
Osteoarthritis, osteochondrosis and synovial sepsis, which can be life-threatening, are 
common articular conditions in which rapid and specific diagnosis, monitoring and 
prognostication remains a challenge for practicing veterinarians. This study has identi fied 
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that the equine synovial fluid proteome exhibits distinctive profile changes between 
osteoarthritis, osteochondrosis, synovial sepsis and healthy joints. Elevated synovial 
abundance of lactotransferrin and decreased insulin-like growth factor-binding protein 6 
were both found to distinguish synovial sepsis from all other study groups. Thus, these 
protein markers may have a future role in clinical practice to enable an earlier and reliable 
diagnosis of synovial sepsis. 
Keywords: synovial fluid, arthropathy, osteochondrosis, osteoarthritis, synovial sepsis,110 equine 
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Introduction 
Articular conditions are common in horses and can result in loss of function, chronic pain 
and/or inability to work, which are important welfare concerns. The most common 
conditions include osteoarthritis (OA), osteochondrosis (OC) and synovial sepsis, which can 
be life-threatening [1]. Despite the high clinical prevalence of these conditions, rapid and 
specific diagnosis, monitoring and prognostication remains a challenge for practicing 
veterinarians, thus, identification of reliable biomarkers of disease is required. Synovial fluid 
(SF) is in direct contact with articular structures and represents an important source of 
biomarker discovery. SF is located within the articular joint cavity, providing a pool of 
nutrients for surrounding tissues but primarily serving as a biological lubricant, containing 
molecules including hyaluronan with low-friction and low-wear properties to articular 
surfaces [2]. As SF is in close proximity to articular tissues primarily altered during joint 
pathology, this biofluid is an important first approach source for biomarker discovery [3, 4]. 
 
Total protein content in synovial fluid is associated with presence of articular pathology and 
is one of the parameters most commonly used in equine clinical practice to enable diagnosis 
and to monitor horses with synovial sepsis [5]. Problematically there are large overlaps in 
the ranges of SF total protein content among arthropathies, and total protein content is also 
affected by articular diagnostic procedures and treatments [6]. This situation can lead to 
erroneous interpretations and clinical decisions, representing an important welfare risk to 
the horse. More specific proteins such as the acute phase inflammatory protein serum 
amyloid A has been investigated as a potential biomarker of articular conditions in horses 
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[7]; however, it is easily affected by the systemic condition of the patient, and therefore, can 
be unreliable for specific clinical diagnosis [8]. 
 
Proteomics encompasses the comprehensive profiling of protein contents. The proteomic 
profile of the synovial fluid is dependent upon articular disease and its characterization has 
allowed the differentiation of OA and rheumatoid arthritis (RA) in man [4]. A recent study 
has identified a subset of proteins differentially expressed in OA versus normal equine joints  
[9]. Although an increase in total protein is a well-known feature of synovial sepsis, the 
protein profile in synovial sepsis has not been investigated. Identification of a characteristic 
proteomic profile in synovial sepsis would increase the understanding of the molecular basis 
of the condition and also enable the identification of potential biomarkers for early 
diagnosis and treatment of this disease.  
 
A previous study has investigated the equine SF profile in OA and OC compared to healthy 
donors using 2D-gel electrophoresis with subsequent mass spectrometry analysis of in-gel 
tryptic digests. However, few studies have investigated the proteomic profile of equine SF 
using high mass resolution mass spectrometer of in-solution tryptic digestions [9, 10] and, to 
our knowledge, none have investigated protein profile changes in septic SF in any species. In 
this study we have used mass spectrometry and label-free quantification to identify 
potential protein biomarkers that allow differentiation between equine articular joint 
pathologies, potentially aiding accurate diagnosis and enabling increased understanding of 
the effect of septic synovitis on the joint environment. Identification of characteristic 
proteomic profiles in synovial sepsis would increase the understanding of the molecular 
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basis of the condition and also allow the determination of potential biomarkers for early 
diagnosis and treatment of the disease. We hypothesised that proteomic profile 
characteristics will distinguish septic from non-septic equine arthropathies and between the 
non-septic common arthropathies OC and OA. The objective of the study was to identify 
possible synovial biomarkers in equine arthropathies. 
Keywords: synovial fluid, arthropathy, osteochondrosis, osteoarthritis, synovial sepsis, 
equine 
 
Methods  
All chemicals were supplied by Sigma-Aldrich (Gillingham, UK) unless otherwise stated. 
Sample collection  
Following ethical approval and owner consent, excess aspirated SF (collected during clinical 
diagnostic investigations) was analysed from joints of horses presenting to The Philip 
Leverhulme Equine Hospital, University of Liverpool between 2014 and 2016, diagnosed 
with clinical OA, OC and synovial sepsis. Clinical diagnoses were determined via a 
combination of radiography, ultrasonography, arthroscopy and SF analysis and/or bacterial 
culture as previously described [11]. SF was aspirated for diagnostic purposes from the 
affected joints during patient examinations or at the start of surgical arthroscopy under 
general anaesthesia. SF was immediately placed into EDTA-containing tubes (BD Vacutainer, 
Belliver Industrial Estate, Plymouth, UK) and particulate and cells were removed from the SF 
by centrifugation (4oC, 2540g for 4 min). The cell-free supernatant was transferred to a 
clean uncoated 1.5 ml collection tube, snap-frozen using liquid nitrogen and stored at -80oC. 
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SF was collected from the distal interphalangeal, femorotibial, glenohumeral, intercarpal, 
metacarpophalangeal, metatarsophalangeal, patellofemoral and tarsocrural joints.  
Eight healthy synovial fluid (SF) samples were obtained from the metacarpophalangeal joint 
of mixed breeds of horses from an abattoir with no gross joint changes, with a total score of 
0 according to the Mcilwraith et al. gross scoring system, scored by two independent 
assessors[12]. Samples were collected as a by-product of the agricultural industry and 
processed within 12 hours of euthanasia. The Animals (Scientific Procedures) Act 1986, 
Schedule 2, does not define collection from these sources as scientific procedures and 
ethical approval was therefore not required. Post-mortem SF samples were processed using 
identical protocols as for clinically collected hospital samples. Final groups consisted of OA 
(n=4), OC (n=8), synovial sepsis (n=7) and healthy (n=8) (full details in Supplementary File 1). 
 
Synovial fluid preparation 
SF was thawed and treated with 1µg/ml hyaluronidase as previously described [9] and 
centrifuged at 10000g for 10 min to remove any particulates. Protein concentrations of SF 
were determined by Bradford assay (Thermo Scientific, USA). A volume of sample 
equivalent to 5mg of protein was added to 10 µL of beads [9]. SF samples were enriched for 
low abundance proteins using ProteoMiner™ beads (BioRad, UK) according to the 
manufacturer’s instructions. Beads were re-suspended in 80 µL of 25 mM ammonium 
bicarbonate and 5 µL of 1% (w/v) Rapigest SF (Waters, UK) added and the sample heated at 
80˚C for 10 min. On bead trypsin digestion was undertaken [9].   
 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) and label-free quantification 
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Tryptic digests (samples were diluted 5-fold in 0.1% (v/v) TFA/3% (v/v) acetonitrile and 2 µL 
loaded) were subjected to LC-MS/MS, using a 2 hr gradient. Data-dependent LC-MS/MS 
analyses were conducted on a QExactive HF quadrupole-Orbitrap mass spectrometer 
(Thermo Scientific, Hemel Hempstead, UK) coupled to a Dionex Ultimate 3000 RSLC nano-
liquid chromatograph (Thermo Scientific). Sample digests were loaded onto a trapping 
column (Acclaim PepMap 100 C18, 75 µm x 2 cm, 3 µm packing material, 100 Å) using a 
loading buffer of 0.1% (v/v) trifluoroacetic acid, 2 % (v/v) acetonitrile in water for 7 min at a 
flow rate of 12 µL min-1. The trapping column was then set in-line with an analytical column 
(EASY-Spray PepMap RSLC C18, 75 µm x 50 cm, 2 µm packing material, 100 Å) and the 
peptides eluted using a linear gradient of 96.2 % A (0.1 % [v/v] formic acid):3.8 % B (0.1 % 
[v/v[ formic acid in water:acetonitrile [80:20] [v/v]) to 50 % A:50 % B over 90 min at a flow 
rate of 300 nL min-1, followed by washing at 1% A:99 % B for 5 min and re-equilibration of 
the column to starting conditions. The column was maintained at 40 oC, and the effluent 
introduced directly into the integrated nano-electrospray ionisation source operating in 
positive ion mode. The mass spectrometer was operated in DDA mode with survey scans 
between m/z 350-2000 acquired at a mass resolution of 60,000 (FWHM) at m/z 200. The 
maximum injection time was 100 ms, and the automatic gain control was set to 3e6. The 12 
most intense precursor ions with charges states of between 2+ and 5+ were selected for 
MS/MS with an isolation window of 2 m/z units. The maximum injection time was 100 ms, 
and the automatic gain control was set to 1e5. Fragmentation of the peptides was by higher-
energy collisional dissociation using normalised collision energy of 30%. Dynamic exclusion 
of m/z values to prevent repeated fragmentation of the same peptide was used with an 
exclusion time of 20 s. 
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For label-free quantification, the raw files of the acquired spectra were analysed by the 
ProgenesisQI™ software (Waters, Manchester, UK) [9] which aligns the files and then peak 
picks for quantification by peptide abundance. Briefly, the top five spectra for each feature 
were exported from ProgenesisQI™ and utilised for peptide identification with our local 
Mascot server (Version 2.6.2), searching against the Unihorse database with 
carbamidomethyl cysteine as a fixed modification and methionine oxidation as a variable 
mod, peptide mass tolerance of 10 ppm and MSMS tolerance of 0.01 Da. In this study we 
define differentially expressed (DE) proteins as those with a greater than 2 fold change in 
expression, with a false discovery rate (FDR) adjusted p value of <0.05, and identified with at 
least two unique peptides  
Proteomic data has been deposited in the PRIDE ProteomeXchange and can be accessed 
using the identifier PXD011276 [13]. 
 
Pathway and network analysis of proteomic data in contrasts of either sepsis, OA or OC 
versus healthy 
Network analysis, canonical pathways and upregulated regulators of proteomics data were 
analysed through the use of IPA (Qiagen, US). Proteins with an FDR adjusted p value of 
<0.05 and with 2 or more unique peptides were used for analysis, uncharacterised proteins 
were not included to the analysis. Gene names from the lists generated by ProgenesisQI™ 
were uploaded on IPA, unmapped genes were converted manually to human orthologues 
and as species mammals were checked for analysis.  
 
Validation of mass spectrometry using ELISA  
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The differentially expressed proteins lactotransferrin (LTF) and insulin-like growth factor-
binding protein 6 (IGFBP6) were selected to validate mass spectrometry findings as they 
could be measured using available enzyme linked immunosorbent assays (ELISAs) that were 
compatible with equine samples. Commercially available kits were used for both equine LTF 
(MBS902183, MyBioSource Inc., San Diego, California, USA) and equine IGFBP6 (abx574245, 
Abbexa Ltd, Cambridge, UK), using sandwich and competitive inhibition ELISA methodology 
respectively. For IGFBP6 analysis, HA treated/Costar processed native SF was diluted 1/10 
whereas for LTF analysis SF was undiluted. 5-6 dependent cohort SF samples were tested 
per group. 100 µl aliquots of each sample were analysed in duplicate, with the absorbance 
measured at 450 nm and protein concentrations calculated from standard curves.  
 
Additional Statistical Analyses 
Principal component analysis (PCA) plots and heat map analysis were produced using 
MetaboAnalyst 4.0. The Venn diagram was produced using the online tool Venny 2.1 and 
box plots constructed using GraphPad Prism 8 and SPSS 24. Statistical analysis of SF protein 
concentration, LTF and IGFBP6 abundances were performed in Minitab version 17. These 
were conducted via ANOVA, using Tukey post hoc testing, with a p value of < 0.05 
considered statistically significant, following correction for multiple testing. 
  
Results 
Protein concentration of SF different arthropathies 
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The SF protein assay demonstrated that concentration was dependant on the type of 
arthropathy (Figure 1).  
 
Differential abundance of proteins in healthy compared to osteoarthritis, osteochondrosis 
and sepsis SF 
From the aggregate data file produced from all samples 1,385 protein families, at a 1% FDR, 
were identified (Supplementary File 2). ProgenesisQI™ identified 750 proteins DE when all 
groups were compared using a 4-way analysis (>2-fold change, FDR<0.05 and identified with 
at least two unique peptides) (Supplementary File 3). The number of protein identifications 
in each analysed group are shown in Figure 2A. The number of DE proteins in 2-way 
contrasts is shown in Table 1 (with complete protein lists shown in Supplementary File 4) 
and multivariate 2-way comparisons of protein profiles shown in Figure 2B. Unsupervised 
multivariate analysis (Principal Component Analysis (PCA)) demonstrated clear variance 
between groups in the 4-way analysis (Figure 3A). 
 
Table 1. Number of proteins DE in two-way comparisons 
Contrast Number of Proteins DE Increased Decreased 
Healthy versus Sepsis 386 205 181 
Healthy versus OA 430 331 99 
Healthy versus OC 539 474 65 
OA versus Sepsis 53 22 31 
OC versus Sepsis 454 75 379 
OA versus OC 0 0 0 
 
DE proteins were filtered to include proteins identified with two or more peptides, q<0.05 
and >2 fold change in expression. 
 
Canonical pathways and network analysis of osteoarthritis, osteochondrosis and sepsis SF 
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Canonical pathway analysis was undertaken on differentially abundant proteins, contrasting 
either OA, OC or sepsis, versus healthy (Supplementary File 5). When sepsis samples were 
compared to healthy it was revealed that the predicted upregulation of coagulation system 
(p =7.94 x 10-23), acute phase response signalling (p =3.98 x 10-19), LXR/RXR activation (p 
=2.51 x 10-17), extrinsic and intrinsic prothrombin activation pathways (p =2 x 10-16 and p =1 
x 10-14), complement system (p =3.16 x 10-11), neuroprotective role of THOP1 in Alzheimer’s 
disease (p =1.55 x 10-6) and OA pathway (p =7.08 x 10-6); and inhibition of matrix 
metalloproteases was downregulated (p =2.51 x 10-15) (Figure 4A). Whereas pathway 
analysis of OA versus healthy demonstrated upregulation of the coagulation system (p =5.01 
x 10-17), complement system (p =1.58 x 10-16), extrinsic and intrinsic prothrombin activation 
pathways (p =5.01 x 10-12 and p =2 x 10-11) (Figure 4B). Comparison of differential abundant 
proteins in OC compared to healthy samples demonstrated an upregulation in complement 
system (p =2 x 10-16) and RhoGDI signalling (p =5.62 x 10-9) (Figure 4C). Downregulated 
canonical pathways of OA or OC versus healthy had a substantial overlap including acute 
phase response (OA p =6.31 x 10-15, OC p =7.94 x 10-11), EIF2 signalling (OA p =7.94 x 10-15, 
OC p =1.26 x 10-23), actin cytoskeleton signalling (OA p =7.94 x 10-13, OC p =1 x 10-12), 
regulation of eIF4 and p7056K signalling (OA p =7.94 x 10-13, OC p =3.98 x 10-15), mTOR 
signalling (OA p =1.58 x 10-11, OC p =3.16 x 10-13), leukocyte extravasation signalling (OA p 
=3.98 x 10-11, OC p =3.98 x 10-11), signalling by Rho family GTPases (OA p =2.82 x 10-10, OC p 
=1.82 x 10-9), p7056K signalling (OA p =8.91 x 10-9, OC p =1.15 x 10-9) and protein kinase A 
signalling (OA p =1.02 x 10-8, OC p =4.9 x 10-8). IGF-1 signalling (p =3.16 x 10-11) and ephrin B 
signalling (p =1.91 x 10-9) were downregulated pathways in OA only; and Fcy receptor-
moderated phagocytosis in macrophages and monocytes (p =1.91 x 10 -10), production of 
nitric oxide and reactive oxygen species in macrophages (p =2.88 x 10-8) present in OC only.  
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Compared to healthy SF, in sepsis there was an upregulation in cellular movement, 
haematological system development, inflammatory response, cell-to-cell signalling and 
immune cell trafficking and this was in distinct contrast to these pathways in OA and OC in 
which they were downregulated (Figure 5A). Similarities between groupings of canonical 
pathways in OA (Figure 5B) and OC (Figure 5C) were identified. The groups of organismal 
injury and abnormalities, and cancer had the highest overlap in healthy versus 
sepsis/OA/OC, however the activation of most pathways could not be predicted by IPA, with 
an overall trend to be downregulated. Organismal injury and cancer had the most overlap in 
healthy versus OA or OC as well. These were predicted to be upregulated in OA compared to 
sepsis and even more upregulated in OC. 
ELISA validation of lactotransferrin and Insulin-like growth factor-binding protein 6 
LTF ELISA assay results corroborated mass spectrometry findings with a statistically elevated 
abundance present within sepsis SF samples compared to all other groups (Figure 7). IGFBP6 
ELISA results produced a similar trend to that identified via mass spectrometry; however 
these results were not of statistical significance. 
 
Discussion 
Articular pathologies have an important clinical relevance in horses; however, to date the 
veterinary practitioner can find it difficult to achieve a timely diagnosis and prognostication 
of these conditions in horses affected by joint pathologies. This study has confirmed that SF 
protein concentration is associated with the type of arthropathy and has identified 
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pathways and possible markers that may enable further understanding, together with rapid 
and accurate identification of these conditions in horses and potentially other species. For 
the first time the study of the proteomic profile of SF has identified potential SF markers of 
synovial sepsis. The proteomic profile can discriminate between septic and non-septic 
articular pathologies, and between non-septic conditions such as OC and OA. The 
implications highlighted by protein changes attributable to different pathways has increased 
our knowledge on articular pathophysiology.  
 
Within this study, elevated synovial levels of lactotransferrin (LTF) were identified within the 
sepsis group compared to the other pathologies. LTF, also known as lactoferrin, is an 80 kDa 
multifunctional glycoprotein, abundant in various biofluids, primarily transporting iron ions, 
but also exhibiting anti-microbial, anti-inflammatory, and immune modulatory effects [14-
16] LTF provides anti-bacterial action against various bacterial species, inhibiting the growth 
of Staphylococcus epidermidis, antibiotic-resistant Klebseilla and Staphylococcus aureus in 
vitro and reducing blood and hepatic infection severity following Escherichia coli enteral 
infection in rats [17-20] LTF is present within specific granules of neutrophils with elevations 
in LTF levels potentially representing a marker of neutrophil granulocyte activation [21]. LTF 
levels within human SF have been found to be closely correlated to the level of SF 
neutrophilia, indicating the degree of inflammatory response [22]. Various studies on SF 
from RA patients have identified increased synovial levels of LTF [23-25]. LTF has been found 
to activate expression of bone morphogenetic protein 7 (BMP7) within porcine articular 
chondrocytes, through the mitogen-activated protein kinase ERK pathway [26]. As BMP7 has 
an important role in maintaining homeostasis of articular cartilage, the authors proposed 
LTF exhibits a protective function following inflammation within the joint.  During synovial 
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sepsis, there is an upregulation of collagen catabolism due to an increased cytokine 
concentration leading to the release of matrix metalloproteinases [27]. Thus, following 
synovial sepsis the release of LTF from neutrophil granulocytes may have a multi -functional 
role, both providing a direct antibacterial function and enabling a degree of 
chondroprotection. Clinically, LTF diet supplementation of neonates has demonstrated an 
ability to reduce the occurrence of late onset sepsis [19, 28-30]. However, elevations in 
synovial LTF levels have not previously been identified as a marker of synovial sepsis. 
In this study, reduced SF IGFBP6 was identified within the sepsis group compared to other 
joint pathologies. This protein is involved in cartilage and bone homeostasis but is also 
expressed in the synovium, particularly in RA versus OA [31]. IGFBP6 is a 30 kDa protein 
which is secreted into extracellular regions where it can subsequently interact with insulin 
growth factors (IGFs). IGFBP6, unlike other IGFBPs, binds to IGF2 with higher affinity than 
IGF1, inhibiting IGF2 activity [32]. IGFBP6 has previously been identified in human SF, with 
synovial levels decreased in RA compared to OA [31]. Postoperative sepsis significantly 
alters the growth hormone/IGF axis, reducing GH-dependent molecule secretion (i.e. 
IGFBP3) and increasing GH-independent molecule secretion (i.e. IGFBP6) [33]. However, 
decreased levels of synovial IGFBP6 have not previously been identified for synovial sepsis in 
horses. IGFBPs are known regulators of insulin resistance, with increased serum IGFBP6 
levels identified within type 1 diabetes, and thus high systemic glucose [34]. Reduced 
synovial glucose concentrations is a known clinical parameter associated with synovial 
sepsis [35]. Thus, the localised reduced abundance of IGFBP6 may be reflective or the 
decreased synovial glucose levels. 
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Protein differences were greatest between synovial sepsis and other groups probably 
reflecting the more distant pathological pathways implicated. Pathway analysis of DE 
proteins in sepsis compared to healthy revealed upregulation of a number of canonical 
pathways including the coagulation system, acute phase response signalling and 
complement system. Systemic inflammation results in activation of coagulation, due to 
tissue factor-mediated thrombin generation, downregulation of physiological anticoagulant 
mechanisms, and inhibition of fibrinolysis [36]. In healthy SF, coagulation proteins have a 
low abundance with the elevated SF levels identified within sepsis in our study probably due 
to thrombin activation and coagulation, also reported in inflamed human joints [37]. In an 
equine model of joint inflammation changes in fibrinogen and thrombin/antithrombin have 
also been reported [38]. The upregulation in sepsis of the acute phase response signalling 
pathway is supports findings of our group and others that acute phase proteins such as 
serum amyloid A increase in equine joint sepsis [11, 39].  
The upregulation of the complement system in joint sepsis is not unexpected. The 
complement system is one of the key players in the defence against infections [40]. Its 
activation during the innate immune response leads to the generation of several proteins 
that contribute to the lysis and opsonisation of microorganisms, regulate inflammatory 
reactions and bridge innate immunity with the subsequent adaptive immune response. 
Depletion in the complement system in animal models increases the severity of septic 
arthritis [41].  
Interestingly eukaryotic translation initiation factors (EIF2) and mTOR signalling were 
downregulated pathways in both OA and OC compared to healthy SF. OC is a juvenile 
osteoarticular disorder affecting several mammalian species. In horses, it is a multifactorial 
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disease with focal disruption of endochondral ossification leading to the development of 
osteoarticular lesions [42]. Nevertheless, OC pathophysiology is poorly understood. Protein 
synthesis requires cooperation among a large number of polypeptides including ribosomal 
proteins, modification enzymes and ribosome associated translation factors. The initiation 
phase of protein synthesis requires a set of EIFs. A reduction in these proteins in OA and OC 
is interesting as in both conditions there is an imbalance between cartilage protein 
anabolism and catabolism leading to a net loss of cartilage. However there is an increase in 
mTOR in end-stage OA and mTOR is important in maintaining cartilage homeostasis [43]. 
Furthermore signalling through mTOR is an important link between synovitis and structural 
damage in inflammatory arthritis [44]. In OA and OC proteins in the SF in our study may be 
derived from cartilage, subchondral bone or synovium. Further studies are required to 
determine the relevance of these changes at the SF proteome level to the pathogenesis of 
these diseases since mTOR inhibition protects cartilage from experimental OA (42). 
Using IPA we have identified a number of proteins requiring further investigation as 
potential biomarkers of disease and/or therapeutic targets (Supplementary File 5). For 
example, Nuclear factor (erythroid-derived 2) (NFE2L2) was identified as the most 
significantly inhibited upstream regulator in OC. Interestingly although also identified as a 
potential upstream inhibitory regulator in OA the effect in OC was much more significant. 
This master regulator of redox homeostasis regulates the expression of antioxidant proteins 
that protect against oxidative damage triggered by injury and inflammation . It has a 
potentially protective role in joint inflammation and degeneration [45]. We have therefore 
identified a catalogue of proteins for future studies. 
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Healthy SF samples were collected following euthanasia whilst samples from the 
pathological groups were predominantly collected from live horses during clinical 
examination. Thus, it cannot be ruled out that differentially abundant proteins identified 
within the healthy group may be resultant of post mortem change. However, post mortem 
processing took place within 12 hours of euthanasia and therefore the impact on the 
synovial proteome is likely to be minimal. Due to the limited sample sizes included within 
this study, SF aspirated from various joints was included. However, despite the inclusion of 
analysis of SF from multiple sites, the clear separation identified in the proteomic profiles of 
different joint diseases strengthens the conclusion that the differentially expressed proteins 
are resultant of the joint pathology opposed to joint location. Additionally, horses with 
different pathologies investigated within this study may experience changes in 
management, including diet and exercise, which may subsequently influence synovial 
protein composition. However, these systemic effects are likely to have a limited effect on 
the synovial proteome compared to the more significant impact of local joint pathology. 
Within this study, ELISA validations of LTF and IGFBP6 synovial abundances were undertaken 
on the same samples as those used for mass spectrometry analysis due to limited 
availability of additional SF samples. Thus, to confirm the results of this study identifying 
these as potential synovial sepsis markers, further validation needs to be undertaken using 
an independent cohort before these proteins are investigated further. 
 
Conclusion 
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This study has identified that the equine SF proteome exhibits distinctive profile changes 
between OA, OC, synovial sepsis and healthy joints. Elevated synovial abundance of LTF and 
decreased IGFBP6 were both found to distinguish synovial sepsis from all other study 
groups. Thus, these protein markers may have a future role in clinical practice to enable an 
earlier and reliable diagnosis of synovial sepsis.  
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Figure 1. Synovial fluid protein concentrations in equine arthropathies. Protein 
concentrations of SF were determined by Bradford assay. Healthy (n=8), OA (n=4), OC (n=8), 
sepsis (n=7). Significant changes are demonstrated following analysis using ANOVA with 
Tukey’s multiple comparison; ** p < 0.01, **** p < 0.0001. 
Figure 2. Analysis of synovial fluid proteomics. (A) Venn diagram of protein identifications 
for each analysed group. A minimum of 2 unique peptides were required for protein 
identification, with a 1% FDR correction applied. (B) Principal component analysis plots of 
healthy versus OA, healthy versus OC and healthy versus sepsis (FDR<0.05, > 2-fold change 
and identified with at least two unique peptides).  
Figure 3.  Principal component analysis and heat map analyses of healthy, OA, OC and 
sepsis SF samples. (A) Principal component analysis of proteins (FDR < 0.05, > 2-fold change 
and identified with at least two unique peptides) revealed the greatest variability was due to 
the type of arthropathy distinguished by shading (healthy; red, OA; green, OC; blue, sepsis; 
turquoise). (B) Heat maps of the top 100 differentially expressed proteins show 
distinguishable profiles based on arthropathy type. Each column indicates a different 
sample group. Each row indicates one protein. Red shading indicates increased expression 
and blue decreased expression.  
Figure 4. Canonical pathways of differentially abundant proteins in equine synovial fluid of 
(A) sepsis, (B) OA and (C) OC compared to healthy samples. Bars represent the significance 
of the canonical pathway, calculated by a right-sided Fisher’s exact test. The tallest bars 
represent the canonical pathways that are the least likely to have been identified due to 
random chance. Upregulated canonical pathways are shown in orange and downregulated 
pathways in blue. 
Figure 5. Heat map identifying canonical pathway groupings for molecular and cellular 
functions altered in equine synovial fluid of (A) sepsis, (B) OA and (C) OC in comparison to 
healthy samples. Squares are coloured according to their Z score, with orange upregulated 
in the disease state and blue downregulated, with the colour intensity indicating prediction 
strength. The Z score represents whether the up- or downregulation of the proteins within 
that function will lead to activation (positive Z score) or inhibition (negative Z score) of the 
function.  
Figure 6. Network involved in the immune response of cells mapped from the differential 
abundant proteins of septic equine synovial fluid. Red nodes represent greater protein 
abundance in sepsis; green nodes represent lower protein abundance in sepsis; and white 
nodes represent molecules mapped to this network and not present in the dataset. Orange 
arrows represent predicted activation, blue arrows predicted inhibition and yellow arrows 
indicate results inconsistent with the state of downstream molecules.   
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Figure 7. ELISA validation of LC-MS/MS results for lactotransferrin (A and B) and insulin-like 
growth factor binding protein 6 (IGFBP6) (C and D). IGFBP6 normalised to total protein. 
ELISA: n = 5-6/group. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. OA = osteoarthritis, OC = 
osteochondrosis, n.s. = non-significant. 
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Highlights 
 Synovial fluid proteomics discriminated healthy from osteoarthritis, osteochondrosis and sepsis. 
 Increased abundance of lactotransferrin in septic synovial fluid. 
 Reduced abundance of insulin-like growth factor-binding protein 6 in septic synovial fluid. 
 Sepsis upregulates coagulation, acute phase response signalling and complement systems. 
 NFE2L2 was identified as the most significantly inhibited upstream regulator in osteochondrosis. 
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